Chronic cerebrovascular diseases: pathogenetic mechanisms, clinical manifestations, and approaches to therapy
https://doi.org/10.14412/2074-2711-2018-1-83-89
Abstract
The paper gives data on the incidence of cerebrovascular diseases (CVD) and the pathogenetic mechanisms of their development in various common somatic diseases, such as hypertension, atherosclerotic lesions in the great arteries of the head, and diabetes mellitus. It considers data on the occurrence of CVD in more rare diseases, such as hereditary diseases, hyperhomocysteinemia, and migraine. It is noted that the currently available data suggest that that the pathogenetic mechanisms of CVD are heterogeneous and that there are diverse types of cerebral ischemic lesions and their clinical manifestations. Therefore, therapeutic strategies for CVD should take into account not only the clinical features of the disease, but also the mechanisms of its development. The main areas of therapy are highlighted. The use of vasobral to treat CVD is discussed.
About the Author
N. V. Pizova
Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases with Medical Genetics and Neurosurgery,
5, Revolutsionnaya St., Yaroslavl 150000
References
1. Гусев ЕИ, Скворцова ВИ, Крылов ВВ. Снижение смертности и инвалидности от сосудистых заболеваний мозга в Российской Федерации. Неврологический вестник. 2007;39(1):128-33. [Gusev EI, Skvortsova VI, Krylov VV. Reduction of mortality and disability from brain vascular diseases in the Russian Federation. Nevrologicheskii vestnik. 2007; 39(1):128-33. (In Russ.)] .
2. Денисова ЕВ. Актуальные вопросы эпидемиологии сосудистых заболеваний головного мозга в мире (обзор литературы). Вестник общественного здоровья и здравоохранения Дальнего Востока России. 2011;(3): 4-5. [Denisova EV. Topical issues in epidemiology of brain vascular diseases in the world (literature review). Vestnik obshchestvennogo zdorov'ya i zdravookhraneniya Dal'nego Vostoka Rossii. 2011;(3):4-5. (In Russ.)].
3. Левин ЯИ, Хоув АМ. Хронические цереброваскулярные заболевания: тактика ведения пациентов, роль инстенона в терапии и профилактике. Эффективная фармакотерапия. 2011;(19):22-4. [Levin YaI, Khouv AM. Chronic cerebrovascular disease: clinical management of patients, the role of instenon in the treatment and prevention. Effektivnaya farmakoterapiya. 2011;(19):22-4. (In Russ.)].
4. Alvarez XA, Ruether E, Moessler H. Efficacy of cerebrolysin in moderate to moderately severe Alzheimer's disease. In:Research and practice in Alzheimer's disease. Vol. 5. Paris: Serdi Publishing, New York: Springer Publishing Company;2001. P. 179-86.
5. Szapary L, Horvath B, Marton Z, et al. Hemorheological disturbances in patients with chronic cerebrovascular diseases. Clin Hemorheol Microcirc. 2004;31(1):1-9.
6. Erkinjuntti T, Roman G, Gauthier S, et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004 Apr;35(4):1010-7. Epub 2004 Mar 4.
7. Преображенская ИС, Яхно НН. Болезнь Альцгеймера: патогенез, клиника, лечение. Русский медицинский журнал. 2002;10(25): 1143-7. [Preobrazhenskaya IS, Yakhno NN. Alzheimer's disease: pathogenesis, clinic, treatment. Russkii meditsinskii zhurnal. 2002;10(25): 1143-7. (In Russ.)].
8. Скворцова ВИ. Снижение заболеваемости, смертности и инвалидности от инсультов в Российской Федерации. Материалы II Российского Международного конгресса «Цереброваскулярная патология и инсульт». 17–20 сентября 2007 г., Инсульт, спецвыпуск. Санкт Петербург; 2007. С. 25-9. [Skvortsova VI. Reduction of morbidity, mortality and disability from strokes in the Russian Federation. Materialy II Rossiiskogo Mezhdunarodnogo kongressa «Tserebrovaskulyarnaya patologiya i insul't». 17–20 sentyabrya 2007 g., Insul't, spetsvypusk [Proceedings of the II Russian international Congress «Cerebrovascular pathology and stroke». September 17-20, 2007, Stroke, special issue]. Saint Petersburg; 2007. P. 25-9.]
9. Sachdev PS, Brodaty H, Valenzuela MJ, et al. The neuropsyhological profile of vascular cognitive impairment in stroke and TIA patients. Neurology. 2004 Mar 23;62(6):912-9.
10. Гусев ЕИ, Скворцова ВИ. Ишемия головного мозга. Москва: Медицина; 2003. 320 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Cerebral ischemia]. Moscow: Meditsina; 2003. 320 p.]
11. Гусев ЕИ. Скворцова ВИ. Ишемия головного мозга. Москва: Медицина; 2001. 248 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Cerebral ischemia]. Moscow: Meditsina; 2001. 248 p.]
12. Goldstein LB. Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001 Jan;32(1):280-99.
13. Стуров НВ, Манякин ИС, Басова ЕА. Сосудистая энцефалопатия при артериальной гипертензии как сочетание когнитивных нарушений и органического поражения головного мозга. Трудный пациент. 2011;9(1):26-9. [Sturov NV, Manyakin IS, Basova EA. Vascular encephalopathy at arterial hypertension as a combination of cognitive impairment and organic brain damage. Trudnyi patsient. 2011;9(1):26-9. (In Russ.)].
14. Дамулин ИВ, Парфенов ВА, Скоромец АА, Яхно НН. Нарушения кровообращения в головном и спинном мозге. В кн.: Яхно НН, Штульман ДР, редакторы. Болезни нервной системы: руководство для врачей. Москва; 2003. 275 с. [Damulin IV, Parfenov VA, Skoromets AA, Yakhno NN. Circulatory disorders in the brain and spinal cord. In: Yakhno NN, Shtul'man DR, editors. Bolezni nervnoi sistemy. Rukovodstvo dlya vrachei [Diseases of the nervous system. A guide for physicians]. Moscow; 2003. 275 p.]
15. Bowler JV, Hachinski V. The concept of vascular cognitive impairment. In: Erkinjuntti T, GauthierS, editors. Vascular cognitive impairment. Martin Dunitz; 2002. P. 9-26.
16. Парфенов ВА. Дифференциальный диагноз и лечение дисциркуляторной энцефалопатии. Consilium Medicum. 2013;(9):28-32. [Parfenov VA. Differential diagnosis and treatment of dyscirculatory encephalopathy. Consilium Medicum. 2013;(9):28-32. (In Russ.)].
17. Захаров ВВ. Клиника, диагностика и лечение дисциркуляторной энцефалопатии. Русский медицинский журнал. 2009;(2): 140-5. [Zakharov VV. The clinic, diagnosis and treatment of dyscirculatory encephalopathy. Russkii meditsinskii zhurnal. 2009;(2):140-5. (In Russ.)].
18. Захаров ВВ, Вахнина НВ. Когнитивные нарушения при цереброваскулярных заболеваниях. Эффективная фармакотерапия. Неврология и психиатрия. 2014;(1):14-22. [Zakharov VV, Vakhnina NV. Cognitive impairment in cerebrovascular diseases. Effektivnaya farmakoterapiya. Nevrologiya i psikhiatriya. 2014;(1):14-22.]
19. Kanner AM. Depression in neurological disorders. Lundbec Inst; 2005. 161 p.
20. Табеева ГР. Головная боль: руководство для врачей. Москва: ГЭОТАР-Медиа; 2014. 188 с. [Tabeeva GR. Golovnaya bol'. Rukovodstvo dlya vrachei [Headache. A guide for physicians]. Moscow: GEOTAR-Media; 2014. 188 p.].
21. Головачева ВА, Парфенов ВА. Хроническая ежедневная головная боль под маской дисциркуляторной энцефалопатии. Медицинский совет. 2015;(2):72-7. [Golovacheva VA, Parfenov VA. Chronic daily headache under the guise of dyscirculatory encephalopathy. Meditsinskii sovet. 2015;(2): 72-7. (In Russ.)].
22. Замерград МВ. Головокружение у пациентов с диагнозом дисциркуляторная энцефалопатия. Медицинский совет. 2014;(5): 22-6. [Zamergrad MV. Dizziness in patients diagnosed with dyscirculatory encephalopathy. Meditsinskii sovet. 2014;(5):22-6. (In Russ.)].
23. Hall CD, Heusel-Gillig L, Tusa RJ, Herdman SJ. Efficacy of gaze stability exercises in older adults with dizziness. J Neurol Phys Ther. 2010 Jun;34(2):64-9. doi: 10.1097/NPT. 0b013e3181dde6d8.
24. Толмачева ВА, Парфенов ВА. Причины головокружения у пациентов с артериальной гипертензией и его лечение. Врач. 2007;(4):49-53. [Tolmacheva VA, Parfenov VA. The causes of dizziness in patients with arterial hypertension and its treatment. Vrach. 2007; (4):49-53. (In Russ.)]
25. Парфенов ВА, Старчина ЮА. Когнитивные нарушения у пациентов с артериальной гипертензией – начальные проявления сосудистой патологии головного мозга. Неврология, нейропсихиатрия, психосоматика. 2011;3(1):27-33. [Parfenov VA, Starchina YuA. Cognitive disorders in patients with essential hypertension and their treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1):27-33. (In Russ.)]. doi: 10.14412/2074-2711-2011-130.
26. Пизова НВ, Дружинин ДС. Патогенез и лечение хронических ишемических цереброваскулярных заболеваний. Неврология, нейропсихиатрия, психосоматика. 2010; 2(4):36-41. [Pizova NV, Druzhinin DS. Chronic ischemic cerebrovascular diseases: pathogenesis and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;2(4): 36-41. (In Russ.)]. doi: 10.14412/2074-2711-2010-114
27. Верещагин НВ, Моргунов ВА, Гулевская ТС. Патология головного мозга при атеросклерозе и артериальной гипертонии. Москва: Медицина; 1997. 288 с. [Vereshchagin NV, Morgunov VA, Gulevskaya TS. Patologiya golovnogo mozga pri ateroskleroze i arterial'noi gipertonii [Pathology of the brain in atherosclerosis and hypertension]. Moscow: Meditsina; 1997. 288 p.]
28. Diabetes Atlas. 51th edition. International Diabetes Federation; 2011.
29. Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care. 2008 Jun;31(6):1260-6. doi: 10.2337/dc08-zb06.
30. Censori B, Manara O, Agostinis C, et al. Dementia after first stroke. Stroke. 1996 Jul; 27(7):1205-10.
31. Шишкова В, Зотова Л, Шкловский В. Цереброваскулярные осложнения у больных с сахарным диабетом. Врач. 2013;(9): 21-5. [Shishkova V, Zotova L, Shklovskii V. Cerebrovascular complications in patients with diabetes mellitus. Vrach. 2013;(9):21-5. (In Russ.)].
32. Ferro JM, Massaro AR, Mas JL. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol. 2010 Nov;9(11): 1085-96. doi: 10.1016/S1474-4422(10)70251-9.
33. Pavlakis SG, Phillips PC, Di Mauro S, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984 Oct; 16(4):481-8.
34. Goto Y, Nonaka I, Horai S. Amutationinthet RNA(Leu) (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990 Dec 13;348(6302):651-3.
35. Sweeney MG, Bundey S, Brockington M, et al. Mitochondrial myopathy associated with sudden death in young adults and a novel mutation in the mitochondrial DNA transfer RNA [Leu(UUR)] gene. Q J Med. 1993 Nov;86(11): 709-13.
36. Morten KJ, Cooper JM, Brown GK, et al. A new point mutation associated with mitochondrial encephalomyopathy. Hum Mol Genet. 1993 Dec;2(12):2081-7.
37. Goto Y, Nonaka I, Horai S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episode (MELAS). Biochim Biophys Acta. 1991 Oct 21;1097(3):238-40.
38. Manfredi G, Schon EA, Moraes CT, et al. A new mutation associated with MELAS is located in a mitochondrial DNA polypeptide-coding gene. Neuromuscul Disord. 1995 Sep;5(5):391-8.
39. Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology. 1992 Mar;42(3 Pt 1):545-50.
40. Ohama E, Ohara S, Ikuta F, et al. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol. 1987;74(3):226-33.
41. Kaufmann P, Shungu DC, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology. 2004 Apr 27;62(8):1297-302.
42. Вельтищев ЮЕ, Темин ПА, редакторы. Наследственные болезни нервной системы. Москва: Медицина; 1998. С. 346–471. [Vel'tishchev YuE, Temin PA, redaktory. Nasledstvennye bolezni nervnoi sistemy [Hereditary diseases of the nervous system]. Moscow: Meditsina; 1998. P. 346–471.]
43. Ban S, Mori N, Saito K, et al. An autopsy case of mitochondrial encephalomyopathy (MELAS) with special reference to extra-neuromuscular abnormalities. Acta Pathol Jpn. 1992 Nov;42(11):818-25.
44. Iizuka T, Sakai F, Kan S, Suzuki N. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology. 2003 Nov 11;61(9):1238-44.
45. Karppa M, Syrajala P, Tolonen U, et al. Peripheral neuropathy in patients with the 3243A>G mutation in mitochondrial DNA. J Neurol. 2003 Feb;250(2):216-21.
46. Suzuki T, Fujino T, Sugiyama M, Ishida M. A case of mitochondrial encephalomyopathy (MELAS). Nihon Jinzo Gakkai Shi. 1996 Feb; 38(2):109-14.
47. Ophoff RA, DeYoung J, Service SK, et al. Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1 -p21.3. Am J Hum Genet. 2001 Aug;69(2):447-53. Epub 2001 Jun 28.
48. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology. 1997 Nov; 49(5):1322-30.
49. Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy. A new hereditary syndrome. Ophthalmology. 1988 May;95(5):649-59. 50. Finkelstein JD, Mudd SH, Irreverre F Laster L. Homocystinuria due to cystathionine synthetase deficiency: the mode of inheritance. Science. 1964 Nov 6;146(3645):785-7.
50. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008 May 7;299(17): 2027-36. doi: 10.1001/jama.299.17.2027.
51. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007 Jun;4(2):143-50.
52. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction (PDF). N Engl J Med. 2006 Apr 13;354(15): 1578-88. Epub 2006 Mar 12.
53. Soliman EZ, Shalash OA. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr. 2008 Apr;87(4):1069-70; author reply 1070-1.
54. Kavakli HS, Altintas ND, Fatih T. Homocysteine Levels in Acute Ischemic Stroke Patients. Journal of Academic Emergency Medicine. 2010;9(4):169-71. doi: 10.5152/jaem.2010.007
55. Homocysteine Studies Collaboration. Homocysteine and risk of ischemicheart disease and stroke: a meta-analysis. JAMA. 2002 Oct 23-30;288(16):2015-22.
56. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007 Jun 2; 369(9576):1876-82.
57. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997 Jun 11;277(22):1775-81.
58. Coull BM, Malinow MR, Beamer N, et al. Elevated plasma homocysteine concentration as a possible independent risk factor for stroke. Stroke. 1990 Apr;21(4):572-6.
59. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995 Nov 25;346(8987): 1395-8.
60. Verhoef P, Hennekens CH, Malinow MR, et al. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke. 1994 Oct;25(10):1924-30.
61. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111-3.
62. Mudd SH, Levy HL, Scovby F. Disorders of transulfuration. In: Scriver CL, Beaudet AL, Sly WS, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th edition. New York: McGraw-Hill; 1995. P. 1279-327.
63. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149-55.
64. Aronow WS, Ahn C, Schoenfeld MR. Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am J Cardiol. 1997 May 15;79(10):1432-3.
65. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocyst(e)ine concentrations and extracranial carotid stenosis. N Engl J Med. 1995 Feb 2;332(5):286-91.
66. Sen S, Reddy PL, Grewal RP, et al. Hyperhomocysteinemia is associated with aortic atheroma progression in stroke/TIA patients. Front Neurol. 2010 Nov 26;1:131. doi: 10.3389/ fneur.2010.00131. eCollection 2010.
67. Табеева ГР. Цереброваскулярные расстройства, ассоциированные с мигренью. Медицинский совет. 2017;(10):32-5. [Tabeeva GR. Cerebrovascular disorders associated with migraine. Meditsinskii sovet. 2017;(10): 32-5. (In Russ.)].
68. Mawet J, Kurth T, Ayata C. Migraine and stroke: in search of shared mechanisms. Cephalalgia. 2015 Feb;35(2):165-81. doi: 10.1177/0333102414550106. Epub 2014 Sep 16.
69. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 Mar;27(3):193-210.
70. Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women. JAMA. 1975 Feb 17; 231(7):718-22.
71. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and metaanalysis of observational studies. BMJ. 2005 Jan 8;330(7482):63. Epub 2004 Dec 13.
72. Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009 Oct 27; 339:b3914. doi: 10.1136/bmj.b3914.
73. Spector JT, Kahn SR, Jones MR, et al. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010 Jul; 123(7):612-24. doi: 10.1016/j.amjmed.2009. 12.021. Epub 2010 May 20.
74. Chabriat H, Joutel A, Dichgans M, et al. Cadasil. Lancet Neurol. 2009 Jul;8(7):643-53. doi: 10.1016/S1474-4422(09)70127-9.
75. Кадыков АС, Шахпаронова НВ. Вазобрал в клинической практике невролога: справочник поликлинического врача. 2011; (7):20-2. [Kadykov AS, Shakhparonova NV. Vazobral in neurologist’s clinical practice. Spravochnik poliklinicheskogo vracha. 2011; (7):20-2. (In Russ.)].
76. Неретин ВЯ, Вострикова ИЛ, Исакова ЕВ и др. Опыт применения препарата «Вазобрал» в лечении дисциркуляторной энцефалопатии. Вестник практической неврологии. 1996;(2):26-8. [Neretin VYa, Vostrikova IL, Isakova EV, et al. Experience of use of «Vazobral» in the treatment of dyscirculatory encephalopathy. Vestnik prakticheskoi nevrologii. 1996;(2):26-8. (In Russ.)].
77. Дамулин ИВ. Некоторые диагностические и терапевтические аспекты нейрогериатрии: справочник поликлинического врача. 2007;(5):44-8. [Damulin IV. Some diagnostic and therapeutic aspects of neurogeriatrics. Spravochnik poliklinicheskogo vracha. 2007; (5):44-8. (In Russ.)].
Review
For citations:
Pizova NV. Chronic cerebrovascular diseases: pathogenetic mechanisms, clinical manifestations, and approaches to therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):83-89. (In Russ.) https://doi.org/10.14412/2074-2711-2018-1-83-89
Views:
778
Email this article 